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6. CTG – Cardiotocogram. 
7. ELISA – Enzyme linked immunosorbent assay. 
8. FFP – Fresh frozen plasma. 
9. GGT – Gamma glutamyltranspeptidase. 
10. IHCP – Intrahepatic cholestasis of pregnancy. 
11. IUD – Intrauterine death. 
12. LDH – Lactate dehydrogenase. 
13. LN – Labour naturale. 
14. LSCS – Lower segment caesarean section. 
15. NICU – Neonatal intensive care unit. 
16. TGL – Triglyceride. 
17. UDCA – Ursodeoxycholic acid. 
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INTRODUCTION 
 
Obstetric cholestasis is a liver disease unique to pregnancy. Once 
assumed to be a benign condition, its significance has been highlighted only 
recently due to associated maternal & perinatal morbidity & mortality. 
 
Its incidence varies with the population. The incidence of obstetric 
cholestasis has been difficult to estimate as a result of likely under reporting 
or failure to recognise mild cases. So, careful history taking and simple 
biochemical tests will be helpful in early diagnosis and appropriate 
intervention in these patients. This will lead to significant reduction in 
maternal and perinatal morbidity and mortality. 
 
As obstetric cholestasis rarely presents with jaundice, and with non 
specific symptoms such as pruritus and disturbed sleep, it is difficult to 
diagnose. 
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AIM OF THE STUDY 
 
To determine the incidence of obstetric cholestasis, study the course 
of pregnancy and evaluate pregnancy outcome in women with obstetric 
cholestasis. 
 
Pregnancy outcome is evaluated in terms of term/preterm/post term 
delivery, Mode of delivery, Meconium staining of liquor, Birth weight of 
baby, NICU admissions, Fetal growth restriction. 
 
The efficacy of UDCA in controlling pruritus is also evaluated. 
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REVIEW OF LITERATURE 
 
EPIDEMIOLOGY 
Due to significant genetic influence, the incidence varies with 
population.Cholestasis is uncommon in North America,with an incidence of 
approximately 1 in 500 to 1000 pregnancies. 
 
In Israel, the incidence reported by Sheiner and associates (2006) is 
approximately 1 in 400. 
 
In Italy,the incidence is 1%.In Sweden, it is 1.5% and in Chile,it is 
4%.In England,it affects 0.7% of pregnancies in multi-ethnic populations 
and 1.2% to 1.5% of pregnancies of Indian-Asian or Pakisthani-Asian 
origin.(1) 
 
There are only limited studies in India and particularly in South India 
and even the few studies which have been conducted have small sample size 
and hence the reliability is very low. 
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PATHOGENESIS 
 
 
Cholestasis (failure of bile formation) represents an exaggerated 
response of the liver to the normal increase in endogenous estrogens during 
pregnancy.Leslie and colleagues (2000) reported that plasma estrogen levels 
are decreased in affected women(2).Bile acids are incompletely cleared by 
the liver and accumulate in plasma. 
There is a role for mutations in the genes that control hepatocellular 
transport systems (3).One of such genes is Multidrug resistance 3 (MDR 3) 
gene found with progressive familial intrahepatic cholestasis. (4).This genetic 
predisposition shows autosomal dominance. 
The elevation in maternal levels of bile acids impairsthe normal feto-
maternal transfer and excess bile acids with abnormal profiles accumulates 
which are toxic to the fetus. 
The drugs which decrease the canalicular membrane transport of bile 
acids aggravate this disorder.There are few case reports of cholestatic 
jaundice in pregnant women taking azathioprine after renal transplantation. 
The end effect is that, bile acids are incompletely cleared and they 
accumulate in plasma. Even before bile acid levels increase, associated 
dyslipidemia is evident.(5) 
Hyperbilirubinemia is due to accumulation of conjugated pigment, but 
the total level never exceeds 4 to 5 mg%. Liver biopsy shows mild 
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cholestasis with bile plugs in hepatocytes and canaliculi of 
centrilobularregions, but without inflammation or necrosis .The changes 
disappear after delivery. Similar changes are seen in women using Oral 
contraceptive pills and cyclically during menstruation.(1) 
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SYNTHESIS OF BILE ACIDS
 (6) 
 
 
Bile consists of a watery mixture of organic and inorganic 
compounds. Phosphatidyl choline and bile salts are quantitatively the most 
important organic components of bile. Bile can either pass directly from the 
liver where it is synthesized into the duodenum through the common bile 
duct, or be stored in the gall bladder when not immediately needed for 
digestion. 
 
Structure of bile acids:-  
The bile acids contain 24 carbons, with two or three hydroxyl groups 
and a side chain that terminates in a carboxyl group. The carboxyl group has 
a pKa of about six and hence it is not fully ionised at physiologic pH and so, 
it is termed as” bile acid”. The bile acids are amphipathic in that the 
hydroxyl groups are in α orientation and the methyl groups are in 
βorientation. Therefore the molecules have a polar and a nonpolar face,and 
can act as emulsifying agents in the intestine, helping prepare dietary 
triacylglycerol and other complex lipids for degradation by pancreatic 
digestive enzymes. 
 
Synthesis of bile acids:-  
Bile acids are synthesized in the liver by a multistep, multiorganelle 
pathway in which hydroxyl groups are inserted at specific positions on the 
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steroid structure, the double bond of the cholesterol B ring is reduced, and 
the hydrocarbon chain is shortened by three carbons, introducingcarboxyl 
groups at the end of the chain. The most common resulting compounds, 
thecholic acid and chenodeoxycholic acid are called primary bile acids. 
 
Synthesis of bile salts:- 
Before the bile acids leave the liver, they are conjugated to a molecule 
of either glycine or taurine (an endproduct of cysteine metabolism).These 
new structures are called bile salts and include glycocholicacid, glycol 
chenodeoxycholicacid, taurocholic, tauro chenodeoxycholicacid. The ratio 
of glycine and taurine forms in the bile is 3:1.Bile salts are more effective 
detergents than bile acids because of their enhanced amphipathic nature. 
Therefore, only the conjugated forms – that is, the bile salts – are found in 
the bile. Individuals with genetic deficiencies in the conversion of 
cholesterol to bile acids are treated with exogenously supplied 
chenodeoxycholic acid. 
 
Bile salts provide the only significant mechanism for cholesterol 
excretion,both as a metabolic product of cholesterol and as a solubiliser of 
cholesterol in bile. 
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Action of intestinal flora on bile salts:- 
Bacteria in the intestine can remove glycine and taurine from bile 
salts,regenerating bile acids. They can also convert some of the primary bile 
acids into secondary bile acids by removing a hydroxyl group producing 
deoxycholic acid from cholic acid and lithocholic acid from 
chenodeoxycholic acid. 
 
Enterohepatic circulation:-  
Bile salts are secreted into the intestine are efficiently reabsorbed 
(greater than 95%) and reused. The mixture of primary and secondary bile 
acids and bile salts is absorbed primarily in the ileum. They are actively 
transported from the intestinal mucosal cells into the portal blood, and are 
efficiently removed by the liver parenchymal cells. The liver converts both 
primary and secondary bile acids into bile salts by conjugation with glycine 
or taurine, and secretes them into bile. The continuous process of secretion 
of bile salts into bile, their passage through duodenum where some are 
converted into bile acids and their subsequent return to the liver as a mixture 
of bile acids and salts is termed as enterohepatic circulation. 
Between 15 and 30 g of bile salts are secreted from the liver into the 
duodenum each day, yet only about 0.5 g is lost daily in the feces. 
Approximately 0.5 g/day is synthesized from cholesterol in the liver to 
replace the lost bile acids.(10) 
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CLINICAL PRESENTATION
 (7) 
Generalised pruritus, which is insidious in onset is the predominant 
symptom. There are no accompanying skin changes unless there are 
excoriations from scratching. Mostly seen in second half of pregnancy. The 
pruritus in this condition, predominantly involves palms and soles but may 
also involve arms, legs, chest, back and face. It may be severe to such an 
extent, it disturbs sleep. 
 
Occasionally, it manifests even earlier. Kirkinen and Rynnanen 
(1995) described a women at 13 weeks with cholestasis associated with 
hyperplacentosis and triploid fetus. 
 
Pruritus usually precedes laboratory findings by a mean of 3 weeks 
and sometimes by months (2). 
 
Other features of cholestasis like dark urine, pale stools may also be 
present. Mild icterus may be present but it is rare. It is present in about 10% 
of cases. The other liver symptoms like nausea, vomiting and abdominal 
pain are typically absent (7). 
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LIVER FUNCTION TESTS IN PREGNANCY
 (7) 
 
LFT 
NON 
PREGNANT 
1
ST
 
TRIMESTER 
2
ND
 
TRIMESTER 
3
RD
 
TRIMESTER 
Bilirubin 
(µmol/L) 
0 - 17 4 - 16 3 – 13 3 - 14 
AST(IU/L) 7 - 40 10 - 28 11 – 29 11 - 30 
ALT(IU/L) 0 - 40 6 - 32 6 – 32 6 - 32 
GGT(IU/L) 7 - 41 5 - 37 4 – 43 3 - 41 
ALP(IU/L) 20 - 125 6 - 375 Increases progressively 
To term 
Albumin(g/L) 35 - 55 Falls by 10g/L Increases progressively 
To term 
Total proteins 
(g/L) 
65 - 80 Falls by 10g/L Increases progressively 
To term 
Globulin(g/L) 30 - 50 Increases progressively 
To term 
Fibrinogen(g/L) 2 - 4 Increases progressively 
To term 
Cholesterol 
(mol/L) 
4 – 6.5 Increases progressively 
To term 
TGL(nmol/L) <1.5 Increases progressively 
To term 
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LIVER FUNCTION TESTS IN OBSTETRIC CHOLESTASIS
 (8) 
 
 Bilirubin – Total bilirubin never exceeds 4-5mg/dl. 
 Serum ALP is usually elevated. 
 Serum transaminases are moderately elevated and never exceed 250 
IU/L. 
 Serum levels of cholicacid,chenodeoxycholic acid and total 3α 
hydroxyl bile acids are elevated from 10 to 100 fold in patients with 
IHCP. 
 As the cholestasis of pregnancy progresses till delivery, the 
biochemical parameters i.e., liver function tests also worsen as 
pregnancy advances. 
 Biochemical abnormalities usually return to pre pregnant levels within 
2 weeks after delivery. If the abnormality persists after 2 weeks of 
delivery, other diagnosis should be considered. 
 Occasionally, serum cholesterol levels may be elevated in intrahepatic 
cholestasis  
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URSO DEOXY CHOLIC ACID
 (9) 
 Category B drug. 
 It is a naturally occurring bile acid used orally to dissolve gall stones. 
 It is a hydroxyl epimer of chenodeoxycholic acid. 
 Absorbed from small intestine and extracted and conjugated by liver. 
 Although 30% - 50% of a dose may enter the systemic circulation, 
continuous hepatic uptake keeps ursodiol blood levels low and uptake 
by tissues other than liver is nil. 
 These factors combined with tight binding to albumin possibly 
indicate that placental passage to fetus does not occur. 
 Mechanism of action  : 
 Acts primarily by inhibiting intestinal cholesterol absorption. It has 
inconsistent effect on HMG-CoA reductase. 
 It also inhibits hepatic cholesterol synthesis but to a lesser extent. It 
promptly reduces cholesterol secretion in bile. 
 It itself lowers the cholesterol saturation index of bile. 
 It promotes solubilisation by liquid crystal formation.  
 For its action, gall bladder should be functional – if the bile is not 
entering gall bladder, it will not be able to solubilise gall stones. 
 Ursodiol is effective in the treatment of IHCP and its use for this 
purpose appears to be low risk for the fetus. 
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 Dose – 8 to 10 mg/kg/day. 
 Other uses – It is primarily being used as a gallstone stabilising 
agent.It has been used successfully in the treatment of intrahepatic 
cholestasis of pregnancy, biliary fistula and liver disease. They are a 
constituent of many combination formulations. 
 Although chenodeoxycholic acid and ursodeoxycholic acid are used 
for similar purposes, their mechanism of action is different. 
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OTHER DRUGS IN TREATMENT OF OBSTETRIC 
CHOLESTASIS
(10) 
There is no evidence that any specific treatment improves fetal or 
neonatal outcomes. All such therapies should be discussed with the 
individual woman with this in mind. 
 
Topical emollients 
Topical emollients are safe but their efficacy is unknown. Bland 
topical options include calamine lotion and aqueous cream with menthol. 
There are no trial data to support or refute the use of these products. They 
are safe in pregnancy and clinical experiencesuggests that for some women 
they may provide slight temporary relief of pruritus. 
 
Systemic treatment 
Systemic treatments aimed at relieving pruritus include 
cholestyramine, a poorly tolerated bile acid-chelating agent, which may 
improve pruritus in some women but may also exacerbate vitamin K 
deficiency(which has been associated with fetal intracranial haemorrhage). 
Cholestyramine has not been subjected to randomised trials and is not in 
clinical use. Antihistamines such as chlorphenamine may provide some 
sedation at night but do not have a significant impact on pruritus. Activated 
charcoal and guargum do not relieve pruritus. 
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S-adenosyl methionine: 
There is insufficient evidence to demonstrate whether S-
adenosylmethionine (SAMe) is effective for either control of maternal 
symptoms or for improving fetal outcome, and it is not recommended. 
 
Plasmapheresis: 
Warren and associates (2005) reported dramatic relief in a women 
with refractory pruritus who was treated by plasmapheresis and 5% albumin 
replacement. 
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OBSTETRIC CHOLESTASIS AND PREGNANCY OUTCOMES
 (11) 
Pregnancy outcomes are adverse in women with cholestaticjaundice. 
There are increased rates of meconium staining of liquor. There is an 
increased incidence of gall stones. 
 
The incidence of preterm labour is 60%.Fetal distress and meconium 
staining of liquor occurs in severe cholestasis. Surprisingly, IUDs and still 
births are seen in clinically mild cholestasis. The risk for IUD and fetal 
distress increase near term. 
 
The mechanism(s) of preterm labour, fetal death and meconium 
staining are not known but these events are attributed to elevated bile acids 
in circulation which increase uterine contractions and fetal colonic muscle 
contractions. 
 
CTG is normal for up to 2 days before fetal demise. Gorelik and 
colleagues (2006) (12) suggest that bile acids may cause fetal cardiac arrest 
after entering cardiomyocytes in abnormal amounts. Using fetal myocyte 
cultures, they showed expression of several genes that may play a role in 
bile transport. 
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PRURITUS IN PREGNANCY
 (8) 
The causes of pruritus in pregnancy are, 
1. Pruritic urticarial papules and plagues of pregnancy. 
2. Prurigo of pregnancy. 
3. Herpes gestationis / pemphigoid gestationis. 
4. Intrahepatic cholestasis of pregnancy. 
5. Pruritic folliculitis of pregnancy. 
6. Non primary pruritic conditions like atopic dermatitis and contact 
dermatitis. 
 
The characteristic feature of pruritus in intrahepatic cholestasis of 
pregnancy is that it predominantly involves palms and soles, is not 
associated with skin rashes except for those excoriations which occur due to 
scratching. It has tremendous adverse psychological impact on the mother as 
it disturbs her sleep. This pruritus responds well to UDCA. Topical 
emollients may have some use. This pruritus completely resolves within 24 - 
48 hours after delivery. 
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DIFFERENTIAL DIAGNOSIS
(11) 
 
The differential diagnosis of intrahepatic cholestasis of pregnancy 
involves other cholestatic conditions such as, 
1. Primary biliary cirrhosis. 
2. Primary sclerosing cholangitis. 
3. Benign recurrent intrahepatic cholestasis (BRIC). 
4. Viral hepatitis. 
5. Biliary obstruction. 
 
Primary biliary cirrhosis and primary sclerosing cholangitis are 
autoimmune disorders and they have anti nuclear and anti smooth muscle 
antibodies. Jaundice is very severe in these patients and dark yellow 
conjunctiva is the most striking feature. 
 
Benign recurrent intrahepatic cholestasis closely resembles 
intrahepatic cholestasis and it is very difficult to differentiate between these 
two conditions. 
 
Viral hepatitis is easily diagnosed by viral marker assays. 
Ultrasonogram diagnoses biliary obstructions with utmost ease. 
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FETAL MONITORING
 (12) 
          Antepartum fetal monitoring is an important aspect in antenatal care 
in patients with obstetric cholestasis as the fetus bears the brunt of this 
disease.  
 
An admission CTG should be done as a baseline. It is not necessary to 
admit all the patients with obstetric cholestasis, but biweekly CTG with AFI 
should be done. If there is any abnormality, pregnancy should be terminated 
irrespective of gestational age. 
 
In case of foetuses which fare normal, some advise to carry pregnancy 
to term and some advise elective termination at 38 weeks. Neonatal 
morbidity and mortality are mainly due to meconium staining of liquor, 
pretermdeliveries, low birth weight and preterm premature rupture of 
membranes. 
 
During labour, continuous intrapartum electronic fetal monitoring 
should be available. As post partum haemorrhage is found to be slightly 
high in patients with obstetric cholestasis, these patients should be carefully 
watched for postpartum haemorrhage. 
28 
 
LIVER IN PREGNANCY
 (13) 
 
Liver size remains normal in pregnancy. Hepatic blood flow and 
hence the diameter of portal vein increases during pregnancy. Histological 
evaluation of liver biopsies, including examination under electron 
microscope, has shown no distinct morphological changes in normal 
pregnant women. 
 
Leucine aminopeptidase is a proteolytic liver enzyme whose serum 
levels are increased with liver disease. Its activity is markedly elevated in 
pregnant women. The increase however results from the appearance of a 
pregnancy specific enzyme(s) with distinct substrate specificities. Pregnancy 
induced aminopeptidase has oxytocinase and vasopressinase activity which 
occasionally causes transient diabetes insipidus. 
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LIVER DISEASES IN PREGNANCY
 (11) 
 
Liver diseases encountered in pregnancy may be coincidental, related 
to pregnancy or may be present even before pregnancy. 
 
Liver disorders related to pregnancy: 
These diseases are induced due to this specific condition, i.e., 
pregnancy and they resolve after delivery. 
These are, 
1. Intrahepatic cholestasis of pregnancy. 
2. Acute fatty liver of pregnancy. 
3. Hyperemesis gravidarum (Hepatic dysfunction). 
4. Severe pre-eclampsia (Hepatocellular damage). 
 
Intrahepatic cholestasis of pregnancy: 
 In most of the cases, it is seen in the second half of pregnancy. 
 Important histological finding – Intrahepatic cholestasis with 
centrilobular bile staining without inflammatory cells or proliferation 
of mesenchymal cells. 
 This is because of high estrogen levels in susceptible women. 
 Incomplete clearing of bile acids in the liver which accumulate in 
plasma.(19) 
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Clinical features : 
 Presenting symptom in most of the cases is pruritus, which is 
generalised. 
 The pruritus in this condition is not accompanied by skin changes 
except that due to skin excoriation due to scratching. 
 Icterus is rare. 
 Liver enzyme levels are elevated, especially those of serum alkaline 
phosphatase and transaminase. 
 
Management : 
Pruritus is extremely troublesome which most often disturbs sleep. 
This can be managed with orally administered anti histaminics and 
Cholestyramine. 
 
Acute fatty liver of pregnancy : 
 Incidence – 1 in 10,000 to 1 in 15,000 pregnancies. 
 An uncommon complication that has proved fatal to both the mother 
and the fetus. 
 Maternal mortality rate – 18%. 
 Fetal mortality rate – 23%. 
 An interesting fact about AFLP is that it is more common in 
nulliparous ladies and in those carrying twins or male fetus.(18) 
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Etiopathogenesis : 
Mitochondrial abnormalities of fatty acid oxidation which are 
recessively inherited predispose a women to this condition. The enzyme, 
long chain 3-hydroxy acyl CoA dehydrogenase (LCHAD) is suggested. 
 
This enzyme is one of the four enzymes which breaks down long 
chain fatty acids in the liver. Deficiency of this enzyme results in increased 
accumulation of long chain fatty acids in the liver. 
 
The most common mutations have been localised to a G1528C 
mutation in over 60% of cases and an E474Q mutation in 19% of the 
cases.These mutations are located on the mitochondrial trifunctional 
complex on chromosome 2. 
 
An individual heterozygous for this mutation, will have no 
abnormalities of fatty acid oxidation under normal circumstances. But, when 
a heterozygous women has a fetus which is homozygous for this mutation, it 
will be unable to oxidise long chain fatty acids. These long chain fatty acids 
accumulate in the fetus and are transferred to the mother via the placenta. As 
a result, triglycerides accumulate within maternal hepatocytes (especially in 
mitochondria) resulting in impaired liver function and in its grave form, to 
liver failure. Delivery of the fetus terminates this process and hence 
maternal liver function improves after delivery. 
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Clinical features: 
It manifests usually in the third trimester, late in pregnancy. The peak 
period of manifestation is 36 – 37 weeks. Sometimes it may occur even after 
delivery. Malaise, anorexia, vomiting, epigastric pain are seen. Coagulation 
failure is an associated feature. 
 
Jaundice is common but not invariable. Nearly 50% of these patients 
will have signs of pre eclampsia. Maternal mortality rate is very 
high.autopsy shows a small soft, yellow and greasy liver. 
 
The size of the liver is usually normal or sometimes small. Pruritus is 
uncommon and would suggest a different liver problem like intrahepatic 
cholestasis of pregnancy. 
 
Liver function tests: 
Moderate elevations of ALT and AST, around 300U/L, are usual but 
some patients may have very high (1000 U/L) and some patients may have 
normal values. Alkaline phosphatase and serum bilirubin are elevated. 
 
Histology 
Swollen hepatocytes, cytoplasm is filled with microvesicular fat with 
central nuclei. All these changes have a centrilobular distribution. 
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Differential diagnosis 
(12) 
1. HELLP syndrome. 
2. Viral hepatitis. 
3. Drug induced hepatitis. 
 
Presence of hypoglycaemia, prolongation of prothrombin time 
andabsence of thrombocytopenia differentiates this condition from HELLP 
syndrome. 
 
Treatment : 
Delivery of the fetusis the cure for this condition. Appropriate 
supportive measures should be kept ready while making arrangements for 
urgent delivery. 
 
Screening : 
As early diagnosis improves outcome, screening for LCHAD 
deficiency should be done in all babies born to mothers who are diagnosed 
to be having AFLP. 
 
Obtaining chorionic villous sampling and amniocentesis can assist in 
prenatal diagnosis if foetuses with LCHAD deficiency. 
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Genetic counselling: 
AFLP can recur in subsequent pregnancies and hence genetic 
counselling should be offered. 
 
Hyperemesis gravidarum : 
Incidence – 0.2 – 1.6 per 1000 deliveries. In this condition, nausea 
and vomiting occur in sufficient levels to cause dehydration. It usually 
occurs during first trimester of pregnancy but may occur as late as 20th 
week. 
Due to excessive vomiting, hepatic dysfunction occurs which usually 
requires hospitalisation. Abnormal liver enzyme levels have been reported in 
up to 50% of patients hospitalised for hyperemesis. 
 
Etiopathogenesis : 
Genetic predisposition and high circulating levels of estrogen are 
thought to be causative factors. 
 
Liver function tests : 
There may be mild hyperbilirubinemia and liver transaminase levels 
are elevated in half of the patients. Bilirubin levels are usually less than 4 
mg/dl with elevations in both direct and indirect fractions. Alkaline 
phosphatase levels are increased to about twice the normal value and 
aminotransferase levels may be as high as 200 U/L.(19) 
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The mechanism of hyperbilirubinemia is unknown. This condition is 
most probably related to malnutrition and impaired excretion of bilirubin, 
because laboratory test results show that the values return to normal within 
days after resumption of adequate nutrition and restoration of fluid balance. 
 
Treatment: 
Correct diagnosis of the cause and its correction usually improves this 
condition. Psychological support is often not given much importance which 
is of paramount importance in the present changing lifestyle of people. 
 
Fetal outcome : 
The mean birth weight of babies in patients with severe hyperemesis 
gravidarum, defined as loss of more than 5% of birth weight is significantly 
lower than that of the offspring of women with mild hyperemesis 
gravidarum. 
 
Pre eclampsia and eclampsia : 
Hepatic dysfunction is seen in severe pre eclampsia or eclampsia. The 
pathological lesion is periportal haemorrhage, fibrin deposition and 
hepatocyte necrosis. The degree of dysfunction and histological changes 
vary considerably.(19) 
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The characteristic epigastric or substernal pain called pre eclamptic 
angina is attributed to hepatic subcapsular stretching. 
 
Subcapsular hematoma and hepatic rupture rarely develop. The 
hepatic complications that develop due to pre eclampsia and eclampsia are 
grouped together as HELLP syndrome. Weinstein in the year 1982 coined 
the term HELLP. HELLP syndrome is usually associated in 5 – 10% of 
patients with pre eclampsia. Sometimes, it may arise in the absence of either 
hypertension or proteinuria. The exact cause for HELLP syndrome remains 
unclear, but vascular endothelial damage plays an important role. 
H – Hemolysis. 
EL – Elevated liver enzymes. 
LP – Low platelet count. 
 
Criteria for diagnosis 
Hemolysis : 
1. Abnormal peripheral smear. 
2. Bilirubin >/= 1.2 mg/dl. 
3. LDH >/= 600 IU/L. 
 
Elevated liver enzymes : 
1. SGOT >/= 72 IU/L. 
2. LDH >/= 600 IU/L. 
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Low platelets : 
Platelet count </= 100,000 cells/cubic mm. 
Classification based on platelet count : 
1. Class 1 - < 50,000/cubic mm. 
2. Class 2 – 50,000 – 100,000/cubic mm. 
3. Class 3 – 100,000 – 1,50,000/cubic mm. 
 
Treatment of HELLP syndrome : 
 Stabilise the general condition. 
 Fresh blood,FFP. 
 MgSo4 for seizure prophylaxis. 
 Anti hypertensive for BP control. 
 High dose corticosteroid treatment :  
 Dexamethasone 10 mg i.v , 2 doses 6 hours apart, totally 4 doses. 
 Dexamethasone 6 mg i.v 2 doses 6 hours apart, totally 4 doses. 
 
Platelet transfusion is indicated if the platelet count is less than 
20,000/cubic mm. Treatment of liver rupture is that of laparotomy, drainage 
of hemoperitoneum and subhepatic packing.(19) 
The placenta is solely responsible for the hypertensive changes and 
hence the curative treatment for this hepatic dysfunction due to pre 
eclampsia is the delivery of the placenta. 
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Laboratory abnormalities peak 24 to 48 hours post partum and hepatic 
enzyme abnormalities and platelet counts come to normal levels in 2 to 3 
days. 
Differentiation of AFLP from HELLP syndrome may be very 
difficult, but the treatment, i.e., prompt delivery and supportive care is same 
in both the cases. 
 
Liver diseases complicating pregnancy  
Viral hepatitis is the liver disease most often encountered in pregnant 
women. There are five distinct types of viral hepatitis. They are hepatitis 
A,B,C,D,E ; Hepatitis D is caused by the B – associated delta agent. 
 
Clinical Features : 
In clinically apparent cases of viral hepatitis, non specific symptoms 
like nausea, vomiting, headache and malaise precede jaundice by 1 to 2 
weeks. Low grade fever is more common with hepatitis A. When jaundice 
develops, symptoms improve. There may be pain and tenderness over the 
liver.(18) 
Laboratory features : 
Serum aminotransferase levels – their levels vary and do not 
correspond with disease severity. Peak levels of 400 – 4000 U/L are usually 
reached by the time when jaundice develops. Serum bilirubin – the peak 
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levels of serum bilirubin are usually at 5 to 20 mg/dl and they continue to 
rise despite fall in enzyme levels. 
 
Management : 
There is no difference in the management protocol between pregnant 
and non pregnant patients. But, pregnant women with hepatitis require 
hospitalisation and delivery at a well equipped hospital because the maternal 
and perinatal morbidity and mortality is high. 
Termination of pregnancy in hepatitis is practised only for obstetric 
indications. Hepatitis by itself is not an indication for termination of 
pregnancy. 
 
Maternal complications : 
Incidence is more common in the second and third trimesters of 
pregnancy. Hepatic failure is more common in pregnancy. In patients with 
poor socio economic status, malnutrition is more prevalent and this in turn 
predisposes to increased morbidity due to liver failure.(18) 
Hepatic coma is a fatal complication and it is usually encountered in 
patients who die before delivery. In patients after delivery, post partum 
haemorrhage is a fatal complication. 
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Pregnancy in women with pre existing liver disease 
(13) 
The pre existing liver diseases may be  
1. Autoimmune chronic active hepatitis. 
2. Chronic viral hepatitis. 
3. Primary biliary cirrhosis. 
4. Cirrhosis. 
5. Cholestatic disorders. 
6. Wilsons disease. 
7. Hepatic adenoma/focal nodular hyperplasia. 
 
Effect of pregnancy on pre existing liver disease: 
Pregnancy is unusual in patients with chronic liver disease as there is 
a high prevalence of infertility among these group of patients. Fertility 
becomes near normal when cirrhosis is well compensated and when there is 
good improvement in autoimmune diseases due to treatment with steroids. 
The degree of hepatic impairment determines the risk for the mother 
during pregnancy. Haemorrhage from esophageal varices is the most 
significant complication of cirrhosis in pregnancy.The increased blood 
volume and flow through the azygos system that are a part of any normal 
pregnancy raise the pressure in the esophageal veins. In established 
cirrhosis, this increases variceal size and the likelihood of bleeding. 
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Pre-existing chronic liver disease requires careful monitoring of the 
patient, as the disease may worsen during pregnancy.Careful monitoring of 
the fetus is of paramount importance.Most often,women with pre-existing 
liver disease are able to carry the fetus safely to term.(18) 
 
Autoimmune chronic active hepatitis (CALD): 
Flare ups has been reported during pregnancy.However,it is not clear 
whether the flare ups of CALD have actually been induced by 
pregnancy,since autoimmune hepatitis is a disorder characterised by 
exacerbations and remissions. 
 
Prednisone and azathioprine are usually used to treat CALD.These 
can be used safely during pregnancy, and they have no adverse effects on 
the fetus. Pregnant women who have CALD (with or without therapy) have 
a higher incidence of both stillbirths and premature delivery. 
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Chronic viral hepatitis : 
There is little evidence that pregnancy influences the clinical course 
of either chronic active or chronic persistent viral hepatitis. Sometimes, 
worsening of chronic hepatitis B and hepatitis C has been reported. 
 
Primary biliary cirrhosis (PBC): 
Pregnancy often leads to an increase in the biochemical parameters of 
cholestasis in women with primary biliary cirrhosis. Clinically, PBC does 
not exhibit an accelerated course during pregnancy. 
 
After delivery, these abnormalities return to their normal values. As 
PBC tends to occur in older women, PBC and pregnancy are not often seen 
as concomitant problems in same patient. 
 
Cirrhosis : 
Women with cirrhotic liver may carry a pregnancy to term without 
any problem. But the fertility rate is very low in women with cirrhosis. 
However, some cases of worsening hepatic function, jaundice and hepatic 
failure have been reported in pregnant women with cirrhosis. 
 
The risk of variceal haemorrhage is increased in pregnant women with 
cirrhosis. The mode of treatment for variceal haemorrhage during pregnancy 
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is endoscopic ligation or sclerotherapy. Women with cirrhosis have higher 
rates of still births and premature deliveries. 
 
Cholestatic disorders : 
Patients with Dubin-Johnson syndrome demonstrate an increase in 
conjugated bilirubin during pregnancy. Patients with Gilbert syndrome do 
not develop an increase in unconjugated bilirubin during pregnancy. 
 
Patients with the rare syndrome of benign recurrent intrahepatic 
cholestasis (BRIC) usually develop jaundice during pregnancy. Unaffected 
first degree relatives of patients with BRIC develop cholestasis during 
pregnancy. 
 
Wilson’s disease : 
(14) 
It is a very rare disease and it is less commonly encountered during 
pregnancy. It is due to a genetically transmitted disturbance in copper 
metabolism that leads to copper toxicity and death, usually before the age of 
30. 
Treatment – Penicillamine, which is a copper chelator, in a dose of 
0.75 – 1 gm/day. This dosage is safe and is not associated with any 
untoward side effects in the fetus. Compliance to this drug is very much 
important as its discontinuation during pregnancy has been associated with 
worsening of hepatic disease. 
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Hepatic adenoma or focal nodular hyperplasia : 
These are very common hepatic tumors during pregnancy. Although 
these tumors may enlarge and rupture during pregnancy,it is a very rare 
event. 
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HISTORICAL REVIEW 
 
J.Goreth et al and C Williamson et al, from National Heart and 
Lung Institute and Institute of Reproductive and Development biology at the 
Imperial college, London conducted a study to associate obstetric cholestasis 
and still birth and found significant correlation, p < 0.05 between these two. 
The sample size in this study was 72 and this study was conducted over a 
period of two years.(15) 
 
Pilot study for a trial of UDCA and/or early delivery for obstetric 
cholestasis. This study was conducted in Nottingham, England. It was multi 
centered, double blinded, randomised, controlled, factorial design trial. The 
investigating medical officer, pharmacist, and the trial participant will be 
blind to know to which group they are allocated. The study was conducted 
in 6 United Kingdom Centres and women with intrahepatic cholestasis of 
pregnancy will be followed up for 18 months.(16) 
 
Comparison group A – UDCA Vsplacebo. Comparison group B – 
Planned delivery at 37 weeks of gestation Vs awaiting spontaneous delivery 
till term. Sample size – 125.This trial concluded that UDCA and early term 
delivery decreased still birth rate and fetal complications like meconium 
staining of liquor, respiratory distress and low birth weight. 
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Roncaglia N et al and Arreghini A et al from the department of 
Obstetrics and Gynaecology, Monza, Italy studied the outcome of patients 
with obstetrics with active management. This study was conducted between 
January 1989 and December 1997.All women with obstetric cholestasis 
underwent transcervical amnioscopy after 36 weeks of gestation for 
assessment of colour of amniotic fluid and they were also subjected to 
antepartum fetal monitoring, i.e., biweekly non stress test and amniotic fluid 
index.(17) 
 
In severe cases, amniocentesis was done before 36 weeks for 
assessment of fetal lung maturity and amniotic fluid colour assessment. 
Induction of labour was done earlier before 37 weeks in the presence of 
adverse fetal parameters. The outcome of pregnancy was compared between 
the population with obstetric cholestasis and the general population. 
 
Results: The incidence of obstetric cholestasis was 1%.Mean 
gestational age at diagnosis was at 34 weeks. Meconium staining of liquor in 
16%.The meconium staining of liquor before 37 weeks was significantly 
higher in patients with obstetric cholestasis than in the general population 
(17.9% Vs 2.9%).The rate of caesarean section was equal in both groups 
(15.1% Vs 16%). 
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Conclusion : In pregnant patients with obstetric cholestasis, 
practising a protocol, which includes a search for meconium staining of 
liquor and elective termination of pregnancy at 37 weeks of gestation and 
antepartum fetal monitoring, significantly reduces the still birth rate without 
an increase in caesarean section rate. 
 
He j et al,Chen et al,Liang C et al from the department of 
Obstetrics, Women’ shospital, Hangzhou, China conducted a retrospective 
analysis of 21 cases of intrahepatic cholestasis of pregnancy whose foetuses 
succumbed to intrauterine death. This study was conducted from January 
1999 to December 2010.(18) 
 
Results : 
 The mean age of patients with IHCP with fetal death was 30.2+/-4.6 
years. 
 Out of 21 cases, 20 patients were having singleton pregnancy 1 was 
twin gestation. 
 All cases of intrauterine death occurred in third trimester. 
 The average gestational age at which fetal death occurred was 33.8 
weeks of gestation. 
 Perinatal mortality rate in patients with IHCP was 0.418%. 
 All 21 patients had normal vaginal delivery. 
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 Serum glycocholic acid levels were increased in all the 21 cases. 
 18 cases had grade 3 meconium staining of liquor in amniotic fluid. 
 Conclusion : 
 Intrauterine fetal death in patients with IHCP occurs after the onset of 
uterine contractions,either spontaneous or induced. 
 Uptodate, there is no valid investigation by which we can pick up 
impending fetal distress. 
 Before elective termination of pregnancy, an accurate assessment of 
the gravity of the disease and fetal maturity should be done. 
 
Roncaglia et al, Locatelli et al, Arreluni et al conducted a 
randomised control trial comparing the efficacy of S-Adenosyl methionine 
and UDCA in improving biochemical parameters in IHCP. Sample size – 
46.Period of study was from june 1996 to December 2001.The study 
concluded that in the relief of pruritus, in patients with IHCP, UDCA and S-
Adenosyl methionine were equally effective. Concerned to the improvement 
in biochemical parameters, UDCA is more effective than S-adenosyl 
methionine.(19) 
 
Brites D et al conducted a study from university of Lisbon, Portugal 
in the year 2002 on the changes in the bile acid balance in the mother and 
the fetus and its improvement by the use of UDCA. This study concluded 
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that UDCA is effective in reducing maternal and fetal bile acids and hence 
in improving neonatal outcome.(20) 
 
Wong LF et al,Shallow H et al, O’ Connel MP et al, conducted a 
comparative study on the outcome of IHCP over a 27 months period, from 
the Department of Obstetrics and Gynaecology, Dublin, Ireland.(21) 
 
Sample size – 753.The patients were divided into two groups. 
Obstetric cholestasis and idiopathic pruritus of pregnancy groups.The 
idiopathic pruritus of pregnancy group served as controls. 
 
The percentage of preterm labour was 18% Vs 7.7% of controls. Out 
of 151 mothers with obstetric cholestasis,48.3% had total bile acids between 
11-33.9 µmol/L,21.2% had total bile acids > 40 µmol/L and the rest of 
30.5% had total bile acids in the range of 6 and 10.9 µmol/L. In patients 
with obstetric cholestasis and who had preterm delivery, all had increased 
total bile acids more than 11 µmol/L. 
 
This study concluded that IHCP increases preterm delivery, induction 
of labour, NICU admissions, and low birth weight babies. A cut off value 
for serum bile acids for diagnosis of IHCP is more than 11 µmol/L. 
 
Castano G et al, Lucangioli S et al did a study on serum bile acid 
profiles by the method of capillary electrophoresis in obstetric cholestasis. 
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They did the study from Gastroenterology section, J.M. Pennahospital, 
Argentina.(22) 
 
Asymptomatic hypercholanaemia of pregnancy is the elevation of 
serum bile acids above the cut off value in healthy normal women in 
pregnancy.This shows that serum bile acids are elevated in a substantial 
proportion of normal pregnancies. So, it becomes important to distinguish 
AHP from IHCP by studying serum bile acid profiles in these patients. 
 
The study concluded that the women with obstetric cholestasis had 
elevated serum bile acids, free/ conjugated, lithocholic acid (LCA), cholic 
acid (CA), chenodeoxycholic acid (CDCA) than the normal healthy 
pregnant women. 
 
Pregnant women with asymptomatic hypercholanaemia of pregnancy 
had elevated conjugated dihydroxy serum bile acids than patients with 
normal serum bile acids. 
 
This study concluded that there is a significant difference in the 
profile of serum bile acids between patients of obstetric cholestasis and 
normal pregnancies. There is a shift towards hydrophobic bile acid 
compositions in patients with obstetric cholestasis. 
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Egan et al and colleagues from Anu research centre, Department of 
OBGYN, Cork University Maternity hospital, Cork, Ireland, did a study to 
establish reference level for serum bile acids in pregnancy in all trimesters in 
healthy women. It was a cross sectional study. Sample size was 219.(23) 
 
The values of serum bile acids were between 0.3 – 9.8 µmol/L in 216 
women. There was no significant change in these levels all over pregnancy. 
To conclude, serum bile acid levels are constant and consistent throughout 
pregnancy and they are not elevated. Variation in the levels, if present, are 
very minimal. 
 
Pascual MJ et al and colleagues conducted a study from the 
University of Salamanca, Spain, to determine the relationship between 
asymptomatic hypercholanaemia of pregnancy and the metabolites of 
progesterone.(24) 
 
Sample size – 411 healthy pregnant women. Serum bile acids were 
analysed by enzymatic techniques and serum progesterones were analysed 
by ELISA technique. This study concludes that the serum bile acid pattern 
in both the obstetric cholestasis patients and AHP patients are the same. but 
the total serum progesterone levels were low and the levels of progesterone 
metabolites were high in patients with obstetric cholestasis. 
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Brites D et al, Rodriques CM et al from Pharmacy department, 
University of Lisbon, Portugal, conducted a study which compared 20 
healthy women who are non pregnant and 77 women who are pregnant in 
the third trimester of pregnancy. Out of 77 pregnant women, 39 women 
suffered from obstetric cholestasis. Liver function tests including serum bile 
acids (both conjugated and unconjugated forms) were measured by normal 
laboratory techniques.(25) 
 
Conclusion: 
For the early diagnosis of obstetric cholestasis, the accurate and valid 
markers whose efficacy was 100% were, 
1. Serum total bile acid concentration > 11.0 µmol/L. 
2. Cholic/chenodeoxycholic acid >1.5. 
3. Percentage of cholic acid >42%. 
4. Glycine/taurine< 1.0. 
5. Serum concentration of glycocholic acid > 2 µmol/L. 
 
Ambros – Rudolph CM et al and colleagues from the Department 
of Dermatology, Medical University of Graz,Austria. It is a retrospective 
study, sample size – 13.These 13 cases of obstetric cholestasis represented 
6% of all pregnancy associated dermatologic conditions. Secondary skin 
lesions like excoriations were present in 85% of the cases. All patients had 
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elevated serum bile acids and the level of serum bile acids were directly 
proportional to the adverse fetal outcomes. Preterm delivery rate was 100% 
in those patients not treated with UDCA whereas it was only 30% in those 
treated with UDCA.(26) 
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MATERIALS AND METHODS 
 
SELECTION OF CASES: 
INCLUSION CRITERIA: 
 
The antenatal women in late second trimester and third trimester (24 – 
40 weeks of gestational age) attending antenatal clinic, Kilpauk Medical 
College Hospital, Chennai, with complaints of pruritus and who satisfy 
exclusion criteria are included in the study. The period of study is between 
July 2010 and August 2012, for a period of 2 years. 
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EXCLUSION CRITERIA 
 
1. Positive serology for hepatitis A,B,C. 
2. Previous history of gall bladder disease. 
3. Sonographic evidence of gall bladder disease. 
4. Hypertension complicating pregnancy. 
5. Liver function did not normalise within two weeks after delivery. 
6. Autoimmune diseases like primary biliary cirrhosis, autoimmune 
chronic active hepatitis. 
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METHODOLOGY 
 An interview was conducted using a questionnaire. 
 Around 75 patients satisfying above criteria were chosen. 
 LFT including Serum bilirubin, SGOT, SGPT, SAP, GGT was done. 
Patients were followed up with LFT and it was repeated at an interval 
of 2 weeks. 
 LFT is repeated at 2 weeks after delivery. 
 All patients were given Urso Deoxy Cholic Acid (UDCA) 8mg/kg/day 
in two divided doses. 
 Time taken for onset of relief of pruritus was observed. 
 Review of obstetric notes was done for Gestational age, Meconium 
staining of liquor, Mode of delivery, APGAR score, NICU admission, 
Birth weight. 
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SAMPLE SIZE 
The sample size was calculated using the formula, 
 
   
Z 2   P 1 –  P
 d2
 
Z - Constant (1.96). 
P - Prevalence (0.05). 
d - Desired precision (0.05). 
By using this formula, n comes to 72 and the sample size for my study is 75. 
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RESULTS AND ANALYSIS 
 
Results were analysed with computer statistical analysis system. 
Data’s were compared using chi square test. Results were also analysed 
using proportion analysis by OPEN EPI software. 
 
INCIDENCE OF OBSTETRIC CHOLESTASIS: 
1000 patients were screened and 75 were diagnosed as having 
obstetric cholestasis, the incidence being 7.5%. 
50.67
MECONIUM STAINING OF LIQUOR IN 
OBSTETRIC CHOLESTASIS AND MECONIUM STAINING OF 
 
Out of 75 patients with obstetric cholestasis,
found to have meconium staining of liquor.
 
 
95% Confidence Limits for Proportion 37/75 Proportion: 49.33
Fisher's Exact  
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49.33
OBSTETRIC CHOLESTASIS
MECONIUM STAINED
CLEAR LIQUOR
LIQUOR 
 37 patients (49.7%)
 
37.58 %(lower)  61.14%(upper).  
 were 
. 
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AGE GROUP AND MECONIUM STAINING OF LIQUOR 
Out of 37 patients with meconium staining of liquor,17 patients 
(45.9%) belonged to age group of 21 – 24 years. 
TABLE 1 : 
 
   Meconium staining of 
liquor  
   NO YES Total 
Agegroup 18-20 Count 4 4 8 
% within Meconium 
staining of liquor 
10.5% 10.8% 10.7% 
% of Total 5.3% 5.3% 10.7% 
21-24 Count 18 17 35 
% within Meconium 
staining of liquor 
47.4% 45.9% 46.7% 
% of Total 24.0% 22.7% 46.7% 
25-29 Count 14 14 28 
% within Meconium 
staining of liquor 
36.8% 37.8% 37.3% 
% of Total 18.7% 18.7% 37.3% 
30-35 Count 2 2 4 
% within Meconium 
staining of liquor 
5.3% 5.4% 5.3% 
% of Total 2.7% 2.7% 5.3% 
 Total Count 38 37 75 
% within Meconium 
staining of liquor 
100.0% 100.0% 100.0% 
% of Total 50.7% 49.3% 100.0% 
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Mean age of patients with meconium staining of liquor is 23.86 yrs. 
Mean age of patients with normal liquor is 23.95 yrs. 
 
 
Group Statistics 
 
TABLE 2 : 
 
Meconium 
staining of 
liquor 
N Mean 
Std. 
Deviation 
Std. Error 
Mean 
 
Yes 37 23.86 3.250 .534 
No 38 23.95 3.676 .596 
 
P = 0.918 not significant. 
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OBSTETRIC CHOLESTASIS AND BIRTH 
OBSTETRIC CHOLESTASIS AND 
 
Out of 75 patients diagnosed to be having obstetric cholestasis,13 
patients (17.3%) were found 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
95% Confidence Limits for Proportion 13/75 Proportion 17.33
 
 Lower CL
Fisher's Exact 9.565%
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13
WEIGHT OF BABIES
LOW BIRTH WT
NORMAL BIRTH WT
BIRTH WEIGHT OF BABIES
to have low birth weight babies. 
. 
 
Proportion 
(Percent) 
UpperCL
 17.33% 27.81%
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AGE GROUP AND LOW BIRTH WEIGHT 
 
Out of 13 patients who were found to have low birth weight babies,8 
patients.(61.5%)belonged to age group of 21-24 yrs. 
TABLE 3 : 
 
   Birth weight group  
   < 2.5 kg >‗2.5 kg Total 
Agegroup 18-
20y 
Count 7 1 8 
% within birth weight 
group 
11.3% 7.7% 10.7% 
% of Total 9.3% 1.3% 10.7% 
21-
24y 
Count 27 8 35 
% within birth weight 
group 
43.5% 61.5% 46.7% 
% of Total 36.0% 10.7% 46.7% 
25-
29y 
Count 25 3 28 
% within birth weight 
group 
40.3% 23.1% 37.3% 
% of Total 33.3% 4.0% 37.3% 
30-
35y 
Count 3 1 4 
% within birth weight 
group 
4.8% 7.7% 5.3% 
% of Total 4.0% 1.3% 5.3% 
 Total Count 62 13 75 
% within birth weight 
group 
100.0% 100.0% 100.0% 
% of Total 82.7% 17.3% 100.0% 
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33.33%
PARITY AND OBSTETRIC CHOLESTASIS
OBSTETRIC CHOLESTASIS AND PARITY
Out of 75 patients with obstetric cholestasis,50 patients (66.67%) 
were primigravida. 
 
Obstetric cholestasis is more common in primigravida than in 
multigravidas. 
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66.67%
PRIMIGRAVIDA
MULTIGRAVIDA
 
 
50.67%
OBSTETRIC CHOLESTASIS AND MODE OF 
OBSTETRIC CHOLESTASIS AND MODE OF DELIVERY
 
 
Out of 75 patients with obstetric cholestasis,38 patients (50.67%) 
were delivered by LSCS.
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49.33%
DELIVERY
 
LN
LSCS
 
26.67%
OBSTETRIC CHOLESTASIS AND NICU 
OBSTETRIC CHOLESTASIS AND NICU ADMISSION
 
 
Babies of 55 patients with obstetric cholestasis (73.33%) 
admitted in NICU. 
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73.33%
ADMISSIONS
NICU admission
NO
 
were 
21.82%
10.90%
REASONS FOR NICU ADMISSION
 
The reasons for NICU admissions were M
Respiratory distress and Preterm baby.
TABLE 4 : 
 
NICU ADMISSIONS
MECONIUM 
STAINED LIQUOR
RESPIRATORY 
DISTRESS 
PRETERM BABY
 
67.27% of NICU admissions were due to Meconium staining of 
liquor. The remaining 
deliveries. 
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67.27%
NICU ADMISSIONS
MECONIUM STAINING OF 
LIQUOR
RESPIRATORY DISTRESS
PRE TERM BABIES
 
econium staining of
 
 55 100% 
 
37 67.27%
12 21.82%
 6 10.90%
were due to respiratory distress and preterm
 liquor, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Obstetric cholestasis and preterm 
OBSTETRIC CHOLESTASIS AND PRETERM DELIVERY
 
Out of 75 patients with obstetric cholestasis,
preterm deliveries. 
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8%
92%
delivery
 6 patients (8%)  had 
preterm 
term
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MEAN GESTATIONAL AGE AT DIAGNOSIS OF 
OBSTETRICCHOLESTASIS. 
 
Mean GA at diagnosis of obstetric cholestasis was 32 weeks. 
Obstetric cholestasis was diagnosed as earlier as 25 weeks. 
 
0.00%
20.00%
40.00%
60.00%
80.00%
1 WEEK
2 WEEKS
69.33%
ONSET OF RELIEF
ONSET OF RELIEF WITH UDCA
 
52 patients (69.33%) had onset of relief in 1 week.
23 patients (30.67%) had onset of relief in 2 weeks.
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ONSET OF RELIEF
30.67%
ONSET OF RELIEF
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OBSTETRIC CHOLESTASIS AND SERUM BILIRUBIN 
 
Mean serum bilirubin level in patients with obstetric cholestasis is 
0.74 mg/dl. 
 
Highest serum bilirubin value – 0.9 mg/dl. 
Lowest serum bilirubin value – 0.6 mg/dl. 
 
ASSOCIATION BETWEEN SERUM BILIRUBIN AND 
MECONIUM STAINING OF LIQUOR 
TABLE 5 : 
 
Meconium Staining of 
Liquor 
N Mean 
Std. 
Deviation 
Std. Error 
Mean 
Serum bilirubin 
mean 
Yes 36 .74 .080 .013 
No 37 .74 .073 .012 
 
 
P = 0.809 not significant. 
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OBSTETRIC CHOLESTASIS AND SGOT 
 
Mean SGOT level in patients with obstetric cholestasis – 60.5 IU/L. 
Highest SGOT value – 146 IU/L. 
Lowest SGOT value – 22 IU/L. 
 
ASSOCIATION BETWEEN SGOT LEVELS AND MECONIUM 
STAINING OF LIQUOR 
TABLE 6 : 
 
 
Meconium staining 
of liquor 
N Mean 
Std. 
Deviation 
Std. Error 
Mean 
SGOT mean 
1 37 65.65 32.466 5.337 
0 38 55.42 18.686 3.031 
 
 
p = 0.098 not significant. 
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OBSTETRIC CHOLESTASIS AND SGPT 
 
 
Mean SGPT level in patients with obstetric cholestasis – 57.8 IU/L. 
Highest SGPT value – 124 IU/L. 
Lowest SGPT value – 42 IU/L. 
 
ASSOCIATION BETWEEN SGPT LEVELS AND MECONIUM 
STAINING OF LIQUOR 
TABLE 7 : 
 
Meconium staining 
of liquor 
N Mean 
Std. 
Deviation 
Std. Error 
Mean 
SGPT mean 
1 37 62.54 22.665 3.726 
0 38 53.00 13.164 2.136 
 
 
p = 0.028 significant. 
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OBSTETRIC CHOLESTASIS AND GGT 
 
GGT is raised only in 33.33% of patients with obstetric cholestasis. 
Mean GGT level in patients with obstetric cholestasis is 36.4 IU/L. 
Highest GGT value – 66 IU/L. 
 
 
ASSOCIATION BETWEEN GGT LEVELS AND MECONIUM 
STAINING OF LIQUOR 
TABLE 8 : 
 
Meconium staining 
of liquor 
N Mean Std. Deviation 
Std. Error 
Mean 
GGT mean 
1 37 37.22 17.003 2.795 
0 38 35.58 14.899 2.417 
 
 
p = 0.658 not significant. 
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OBSTETRIC CHOLESTASIS AND SAP 
 
Mean SAP level in patients with obstetric cholestasis – 448.6 IU/L. 
Highest SAP value – 786 IU/L. 
Lowest SAP value – 380 IU/L. 
 
ASSOCIATION BETWEEN SERUM SAP LEVELS AND 
MECONIUM STAINING OF LIQUOR 
TABLE 9 : 
 
Meconium 
staining of liquor 
N Mean Std. Deviation 
Std. Error 
Mean 
SAP mean 
Yes 37 469.35 75.535 12.418 
No 38 427.82 70.455 11.429 
 
p = 0.016 significant 
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ASSOCIATION BETWEEN MECONIUM STAINING OF LIQUOR 
AND MODE OF DELIVERY 
 
Out of 37 babies with meconium staining of liquor,24 (64.9%) were 
deliveredbylabournaturale and 13 (35.1%) were delivered by LSCS. 
TABLE 10 : 
 
 
  Meconium Staining of Liquor  
   No Yes Total 
Mode of 
Delivery 
LN 
Count 13 24 37 
% within Meconium 
staining of liquor 
34.2% 64.9% 49.3% 
% of Total 17.3% 32.0% 49.3% 
LSCS 
Count 25 13 38 
% within Meconium 
staining of liquor 
65.8% 35.1% 50.7% 
% of Total 33.3% 17.3% 50.7% 
 Total 
Count 38 37 75 
% within Meconium 
staining of liquor 
100.0% 100.0% 100.0% 
% of Total 50.7% 49.3% 100.0% 
  
 
Chi square – 7.048 
 
p value = 0.08 significant. 
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MODE OF DELIVERY AND NICU ADMISSION 
 
Out of 55 babies admitted in NICU,30 babies (54.5%) were delivered 
by labournaturale and 25 babies (45.5%) were delivered by LSCS.  
TABLE 11 : 
 
 
Chi square – 2.242.   p = 0.134 not significant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   NICU Admission  
   0 1 Total 
Mode of 
delivery 
LN 
Count 7 30 37 
% within NICU 
abdmission 
35.0% 54.5% 49.3% 
% of Total 9.3% 40.0% 49.3% 
LSCS 
Count 13 25 38 
% within NICU 
abdmission 
65.0% 45.5% 50.7% 
% of Total 17.3% 33.3% 50.7% 
 Total 
Count 20 55 75 
% within NICU 
abdmission 
100.0% 100.0% 100.0% 
% of Total 26.7% 73.3% 100.0% 
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DISCUSSION 
 
Obstetric cholestasis is a disease which is highly under reported. It 
was once considered to be a benign condition but it is not so. Its significance 
has been highlighted only recently due to associated maternal and perinatal 
morbidity and mortality. 
 
Meconium staining of liquor and preterm labours many of the times 
go unrecognised as we do not consider about obstetric cholestasis as a cause. 
The aim of my study was to find the incidence of obstetric cholestasis, study 
the course of pregnancy and the pregnancy outcome in patients with 
obstetric cholestasis. 
 
There are only few studies regarding obstetric cholestasis and its 
pregnancy outcome. 
 
The study conducted by Roncaglia et al and Arreghini et al from Italy 
concluded that the incidence of obstetric cholestasis was 1%.The mean 
gestational age at diagnosis was at 34 weeks. The rate of meconium staining 
of liquor  was 16%. In their study, there was no significant correlation 
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between obstetric cholestasis and meconium staining of liquor and this is 
reflected in my study too. 
 
             
 
 
 
 
Wong LF et al, Shallow H et al,O’Connel MP et al conducted a study 
on the outcome of IHCP from Ireland.The percentage of preterm labour  was 
18% in their study while it was 8% in my study. 
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The percentage of meconium staining of liquor in my study was 
49.33% which was very high when compared to all the other studies. The 
mean gestational age at diagnosis was 32 weeks in my study and this goes 
along all the other studies. The rate of preterm delivery is very low in my 
study when compared to aforementioned studies. 
 
Having proved the association of Obstetric Cholestasis with adverse 
fetal outcomes, it becomes necessary to enquire about pruritus (which they 
may not disclose by themselves) in all pregnant women attending AN OP 
and if the answer is yes, carry on with other investigations necessary to 
prove the diagnosis. Careful follow up of patients with good antepartum, 
intrapartum fetal monitoring with appropriate interventions may reduce fetal 
morbidity and mortality. 
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SUMMARY 
 
 
75 antenatal patients out of 1000 screened, who fulfilled the inclusion 
criteriawere included in the study and followed up till 2 weeks after 
delivery. 
 75 patients out of 1000 screened were found to be having obstetric  
Cholestasis (7.5%). 
 Mean age of patients with obstetric cholestasis was 23.5 yrs. 
 Mean birth weight of babies of mothers with obstetric cholestasis was 
2.6 Kg. 
 The incidence of meconium staining of liquor in patients with obstetric 
Cholestasis was 49.33%. 
 The incidence of low birth weight in patients with obstetric cholestasis 
was 17.3%. 
 50.67 % of obstetric cholestasis patients were delivered by LSCS and 
49.33 % were delivered by labour natural. 
 Out of 75 patients with obstetric cholestasis,50 (66.67%) were 
primigravida. 
 Babies of 55 patients with obstetric cholestasis (73.33%) were 
admitted in NICU. 
 Meconium staining of liquor contributed to 67.27% of NICU 
admissions. 
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 The mean gestational age at diagnosis of obstetric cholestasis was 32 
weeks 
 All the patients with obstetric cholestasis were given UDCA and all of 
them were completely relieved of their symptoms.23 patients (30.6%) 
had onset of relief in 2 weeks and 52 patients (69.33%) had onset of 
relief in a week. 
 Mean serum bilirubin level in obstetric cholestasis was 0.74 mg/dl. 
 Highest serum bilirubin value – 0.9 mg/dl. 
 Lowest serum bilirubin value – 0.6 mg/dl. 
 There is no significant correlation between serum bilirubin levels and 
meconium staining of liquor. 
 Mean SGOT levels in patients with obstetric cholestasis is 60.5 IU/L. 
 Highest SGOT value – 146 IU/L. 
 Lowest SGOT value – 22 IU/L. 
 There is no significant correlation between SGOT levels and 
meconium staining of liquor. 
 Mean SGPT levels in patients with obstetric cholestasis is 57.8 IU/L. 
 Highest SGPT value – 124 IU/L. 
 Lowest SGPT value – 42 IU/L. 
 There exists significant correlation between SGPT levels and 
meconium staining of liquor. 
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 GGT is raised only in 33.33% of patients with obstetric cholestasis. 
 Mean GGT levels in patients with obstetric cholestasis is 36.4 IU/L. 
 Highest GGT value – 66 IU/L. 
 Lowest GGT value – 18 IU/L. 
 There is no significant correlation between GGT levels and meconium 
staining of liquor. 
 Mean SAP levels in patients with obstetric cholestasis is 448.6 IU/L. 
 Highest SAP value – 786 IU/L. 
 Lowest SAP value – 380 IU/L. 
 There exists a significant correlation between SAP levels and 
meconium staining of liquor. 
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CONCLUSION 
 The incidence of obstetric cholestasis in the antenatal OP population of 
Kilpauk Medical College, a tertiary care center is 7.5%. 
 Obstetric cholestasis is more common in primigravida than in 
multigravida. 
 There is a significant association between obstetric cholestasis and 
meconium staining of liquor and NICU admissions. 
 Obstetric cholestasis is more common in the age group of 21-24 yrs. 
 The mean gestational age at diagnosis of obstetric cholestasis is 32weeks. 
 There exists a significant correlation between SGPT levels, SAP levels 
and meconium staining of liquor. 
 GGT and SGOT levels do not have significant association with 
meconium staining of liquor. 
 Serum bilirubin levels were normal in all cases of obstetric cholestasis. 
 UDCA provided symptomatic relief in all the patients with obstetric 
cholestasis. 
 The incidence of preterm deliveries in obstetric cholestasis is 8%. 
 There were no cases of prolonged pregnancy and intrauterine growth 
retardation in patients with obstetric cholestasis. 
 The mean birth weight of babies with obstetric cholestasis –2.6 kg. 
 Mode of delivery does not have significant correlation with obstetric 
cholestasis. 
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PROFORMA 
NAME     : 
AGE      : 
ADDRESS     : 
OBSTETRIC SCORE   : 
MENSTRUAL HISTORY  : 
LMP      : 
EDD      : 
GESTATIONAL AGE   : 
CHIEF COMPLAINTS   : 
PRESENT HISTORY   : 
1. Jaundice 
2. Malaise 
3. Insomnia 
4. Skin rash 
5. Anorexia 
6. Dark urine 
7. Pale stools 
8. PIH 
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PAST HISTORY   : 
1. Jaundice 
2. Gall stones 
3. Similar complaints in previous pregnancy 
4. h/o OCPs intake 
5. hypertension 
 
FAMILY HISTORY   : 
H/O obstetric cholestasis in family members 
 
INVESTIGATIONS   : 
1. anti HAV 
2. anti HCV 
3. anti HEV 
4. HBsAg 
5. Sr bilirubin 
6. SGOT 
7. SGPT 
8. SAP 
9. GGT 
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UDCA     : 
DELIVERY DETAILS   : 
1. Date & Time  : 
2. Mode of delivery : 
3. Indication   : 
4. PROM   : 
5. Preterm labour  : 
6. Liquor   : 
7. Birth weight  : 
8. APGAR   : 
9. NICU admission  : 
10. Post partum haemorrhage : 
 
LFT AFTER 2 WEEKS   : 
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1 Nithya 18 1 1 34 o.7 0.7 42 38 48 36 45 18 380 126 LN no yes yes 1 2.4 yes no no 
2 Sathya 18 1 1 36 o.7 0.8 40 32 56 41 57 22 410 66 LN yes yes yes 2 2.5 yes no no 
3 Monica 18 1 1 34 0.6 0.8 42 38 46 38 54 26 432 82 LN yes yes yes 1 2.5 yes no no 
4 Shagidha 19 1 1 28 0.7 0.8 22 42 44 40 64 26 408 110 LN yes yes yes 2 3 yes no no 
5 Priya 20 1 1 32 0.7 0.8 54 36 48 34 45 24 412 78 LSCS no yes yes 1 2.8 no no no 
6 Shobana 20 1 1 34 0.8 0.7 46 34 52 32 28 22 382 92 LN no yes yes 1 2.5 yes no no 
7 Divya 20 1 2 34 0.7 0.8 44 36 54 34 31 27 440 112 LN no yes yes 1 2.8 no no no 
8 Swapna 20 1 1 32 0.7 0.8 58 34 52 30 62 30 442 68 LN yes yes yes 1 2.7 yes no no 
9 Gomathy 21 2 1 33 0.8 0.8 62 40 66 32 22 16 436 94 LN yes yes yes 2 3.1 yes no no 
10 Kousalya 21 2 2 28 0.6 0.7 24 34 42 30 28 18 424 124 LSCS no yes yes 2 2.4 no no no 
11 Suhasini 21 2 2 28 0.8 0.7 68 38 44 38 22 24 412 68 LSCS no yes yes 1 2.5 yes no no 
12 Monisha 21 2 2 30 0.8 0.8 48 38 46 34 71 26 416 84 LSCS no yes yes 1 2.8  no no no 
13 Shakira 21 2 1 33 0.7 0.8 64 38 46 40 32 22 396 86 LN yes yes yes 1 3 yes no no 
14 Kavitha 21 2 1 36 0.7 0.9 68 34 58 22 35 16 456 92 LSCS no yes yes 1 2.8 no no no 
15 Nagalaksh 21 2 1 34 0.8 0.9 64 32 52 38 21 24 398 124 LN no yes yes 1 2.6 no no no 
16 Nandhini 21 2 1 30 0.8 0.8 48 38 46 32 26 24 412 96 LN no yes yes 2 2.8 yes no no 
17 Radhika 21 2 1 32 0.8 0.8 48 32 44 34 58 22 418 78 LSCS no yes yes 2 2.7 no no no 
18 Janaki 21 2 1 34 0.6 0.7 64 34 48 32 24 20 422 68 LSCS no yes yes 1 3.2 yes no no 
19 Malini 21 2 1 32 0.8 0.7 62 32 50 34 22 26 456 92 LN yes yes yes 1 2.7 yes no no 
20 Amudhaval 21 2 1 28 0.7 0.8 24 34 44 30 26 24 386 84 LN yes yes yes 2 2.6 yes no no 
21 Mohana 21 2 1 32 0.6 0.8 66 36 46 32 22 22 424 68 LN yes yes yes 1 2.3 yes no no 
22 Stella 22 2 1 33 0.7 0.9 64 40 54 35 65 20 436 94 LSCS yes yes yes 1 2.7 yes no no 
23 Sathya 22 2 1 31 0.8 0.8 62 38 64 32 27 30 386 86 LSCS no yes yes 1 2.7 no no no 
24 Poongodi 22 2 1 36 0.8 0.7 64 36 46 35 24 11 392 125 LSCS no yes yes 1 2.5 yes no no 
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25 Teenamary 22 2 1 30 0.7 0.7 52 34 54 32 64 16 384 130 LSCS no yes yes 1 2.5 yes no no 
26 Sindhu 22 2 2 32 0.8 0.8 48 32 56 40 26 18 412 98 LSCS yes yes yes 1 2.5 yes no no 
27 Nikitha 22 2 1 34 0.8 0.7 92 40 124 33 74 22 634 136 LSCS yes yes yes 1 2.4 yes no no 
28 Manju 22 2 1 35 0.9 0.7 48 32 48 28 66 24 526 148 LN yes yes yes 1 2.7 yes no no 
29 Kalaiarasi 22 2 1 32 0.7 0.7 52 38 50 30 34 26 424 126 LN no yes yes 2 2.6 yes no no 
30 Jamuna 22 2 1 36 0.8 0.8 86 32 74 30 22 15 542 99 LN yes yes yes 1 2.3 yes no no 
31 Jeevitha 22 2 2 30 0.7 0.7 52 36 48 30 24 16 522 86 LSCS yes yes yes 1 2.7 yes no no 
32 Gajalaksh 22 2 1 32 0.6 0.8 112 32 98 32 47 24 564 88 LN yes yes yes 2 2.75 yes no no 
33 SELVI 22 2 1 36 0.9 0.8 54 36 63 24 45 26 388 94 LSCS no yes yes 1 2.5 yes no no 
34 Indhumath 23 2 1 25 0.7 0.7 52 32 46 30 26 24 428 92 LSCS no yes yes 1 2.2 yes no no 
35 Saritha 23 2 2 27 0.8 0.8 24 40 42 32 18 18 396 94 LN yes yes yes 2 2.4 yes no no 
36 Vanishree 23 2 1 34 0.8 0.8 48 34 54 34 53 20 416 86 LSCS yes yes yes 1 2.4 yes no no 
37 Nalini 23 2 1 33 0.8 0.8 46 34 48 21 24 24 396 112 LSCS no yes yes 1 2.7 yes no no 
38 Sumathy 23 2 1 39 0.7 0.7 68 36 62 30 28 32 382 98 LN no yes yes 1 2.8 no no no 
39 Pattu 23 2 2 28 0.7 0.8 32 34 42 32 27 32 426 86 LN yes yes yes 1 2.8 yes no no 
40 Kalaiarasi 23 2 2 32 0.7 0.7 48 32 46 36 64 28 398 88 LSCS no yes yes 1 2.8 yes no no 
41 Devi 23 2 1 29 0.8 0.7 36 32 42 30 28 26 392 90 LN yes yes yes 1 2.75 yes no no 
42 Muthulaks 23 2 1 35 0.6 0.7 146 34 114 32 22 24 546 99 LN no yes yes 1 3.2 no no no 
43 Jumma 24 2 2 32 0.7 0.7 48 32 46 28 24 26 486 112 LN yes yes yes 1 2.25 yes no no 
44 Sridevi 25 3 2 31 0.9 0.8 44 34 48 30 46 22 446 134 LSCS no yes yes 1 2.75 no no no 
45 Anitha 25 3 1 34 0.8 0.7 58 38 52 36 31 20 426 89 LN yes yes yes 1 2.3 yes no no 
46 Jayanthi 25 3 2 26 0.8 0.8 44 38 42 34 36 24 389 93 LSCS no yes yes 1 3 yes no no 
47 Sandhya 25 3 1 32 0.7 0.8 46 34 52 26 47 26 468 94 LSCS yes yes yes 1 2.75 yes no no 
48 Jagadha 25 3 2 32 0.8 0.8 60 34 58 30 32 24 428 96 LSCS no yes yes 1 2.8 yes no no 
49 Ashwini 25 3 1 30 0.8 0.8 46 32 48 32 22 26 398 124 LN no yes yes 2 2.8 yes no no 
50 Kalaiselvi 25 3 1 34 0.7 0.8 92 32 86 48 27 22 786 126 LSCS no yes yes 1 2.8 no no no 
51 Saranya 26 3 1 36 0.7 0.7 58 34 50 28 53 24 428 122 LSCS no yes yes 1 2.7 no no no 
52 Menaka 26 3 1 34 0.8 0.8 46 34 48 34 21 20 388 114 LSCS no yes yes 1 2.6 no no no 
53 Paramesh 26 3 2 34 0.9 0.7 66 32 58 26 24 18 422 46 LSCS yes yes yes 1 3.1 yes no no 
54 Eswari 26 3 2 34 0.8 0.7 48 34 46 28 65 14 392 96 LN yes yes yes 2 2.5 yes no no 
55 Padmasree 26 3 1 34 0.7 0.8 50 34 52 22 25 24 462 86 LSCS yes yes yes 2 2.8 yes no no 
56 Bharathy 26 3 2 32 0.7 0.8 52 34 62 36 28 26 398 78 LSCS no yes yes 2 2.3 yes no no 
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57 Rajalakshm 26 3 2 30 0.7 0.8 48 37 46 34 26 32 436 74 LSCS yes yes yes 2 3 yes no no 
58 Shyamala 26 3 1 35 0.6 0.8 146 40 102 32 56 22 624 82 LN yes yes yes 2 2.75 yes no no 
59 Saranya 26 3 1 35 0.7 0.7 64 38 66 36 24 20 346 84 LN yes yes yes 2 2.6 yes no no 
60 Chitra 27 3 1 35 0.7 0.8 52 40 48 32 26 18 386 96 LSCS no yes yes 1 2.7 no no no 
61 Loordhu 27 3 2 34 0.7 0.8 114 36 98 28 21 16 654 108 LSCS yes yes yes 1 3 yes no no 
62 Bharathy 27 3 2 28 0.7 0.8 42 37 46 32 28 24 488 92 LSCS yes yes yes 1 2.5 yes no no 
63 Esther 27 3 1 34 0.8 0.7 48 40 52 28 34 22 512 112 LN yes yes yes 2 2.5 yes no no 
64 Saritha 27 3 1 29 0.7 0.8 44 40 51 30 32 20 546 104 LN no yes yes 1 2.75 no no no 
65 Shalini 28 3 2 29 0.7 0.8 46 35 42 32 24 18 426 88 LSCS no yes yes 1 2.4 yes no no 
66 Rajini 28 3 1 32 0.8 0.8 126 34 98 24 45 14 544 92 LN yes yes yes 1 2.6 yes no no 
67 Eswari 28 3 2 34 0.7 0.8 52 32 50 26 24 16 436 106 LSCS no yes yes 1 2.6 no no no 
68 Sajitha 29 3 1 34 0.7 0.7 54 35 48 28 31 22 386 68 LN no yes yes 2 2.75 no no no 
69 Banumathy 29 3 2 38 0.8 0.7 60 34 62 30 28 20 456 86 LSCS no yes yes 2 2.7 no no no 
70 Meenakum 29 3 1 32 0.7 0.8 143 32 76 32 28 24 436 98 LN yes yes yes 1 2.75 yes no no 
71 Usha 29 3 2 32 0.7 0.8 88 34 88 24 46 22 568 86 LSCS yes yes yes 2 2.8 yes no no 
72 Rajeshwari 30 4 2 32 0.9 0.7 96 35 106 22 20 18 482 76 LSCS yes yes yes 2 2.7 yes no no 
73 Devi 30 4 1 31 0.7 0.8 116 34 98 27 22 20 564 84 LN yes yes yes 1 2.2 yes no no 
74 Shanthi 33 4 2 28 0.7 0.8 44 35 50 32 66 24 436 92 LN no yes yes 1 2.7 no no no 
75 Hemalatha 35 4 1 30 0.8 0.7 50 34 46 32 64 14 428 104 LN no yes yes 2 2.8 yes no no 
96 
 
Ethical Committee Certificate 
97 
 
98 
 
99 
 
Ra xg;Gjy; gbtk; ; ; ;; ; ;; ; ;  
Ma;T nra;ag;gLk; jiyg;G   :  
kfsph; kw;Wk; kfg;NgW kUj;Jtj;Jiw : 
fPog;ghf;fk; kUj;Jtf;fy;Y}up   : 
gq;F ngWgthpd; ngaH    : 
gq;F ngUgthpd; taJ    : 
gq;F ngUgthpd; vz;    : 
gq;F ngWgtH ,jid (√) Fwpf;fTk;. 
 
 NkNy Fwpg;gpl;Ls;s kUj;Jt Ma;tpd; tptuq;fs; vdf;F
tpsf;fg;gl;lJ. vd;Dila re;Njfq;fis Nfl;fTk; 
mjw;fhd jFe;j tpsf;fw;fis Nfl;f 
tha;g;gspf;fg;gl;lLs;sJ vd mwpe;J nfhz;Nld;. 
 
 ehd; ,t;tha;tpy; jd;dpr;irahfj; jhd; 
gq;Nfw;fpNwd;.ve;j fhuzj;jpdhNyh ve;j rl;lrpf;fSf;Fk; 
cl;glhky; ehd; ,t;tha;tpy; ,Ue;J tpyfpf; 
nfhs;syhk; vd;Wk; mwpe;J nfhz;Nld;. 
 
 ,e;j Ma;T rk;ge;jkhfNth mij rhHe;J NkYk; Ma;T 
Nkw;nfhs;Sk; NghJ ,e;j Ma;tpy; gq;F ngWk; 
kUj;JtH vd;Dila kUj;Jt mwpf;iffis ghh;g;gjw;F 
vd; mDkjp Njitapy;iy vd mwpe;J nfhs;fpNwhd;. 
 
 ,e;j Ma;tpd; %yk; fpilf;Fk; jftiyNah KbitNah 
gad;gLj;jpf; nfhs;s kWf;fkhl;Nlhd;. 
 
 ,e;j Ma;tpy; gq;F nfhs;s xg;Gf; nfhs;fpNwd;. ,e;j 
Ma;it Nkw;nfhs;Sk; kUj;Jt mzpf;F cd;ikAld; 
,Ug;Ngd; vd;Wk; cWjpaspf;fpNwd;. 
 
 ,e;j Ma;tpy; xUKiw 5 kp ,uj;j ghpNrhjidf;fhf 
vLj;jf; nfhs;sg;gLk; vd;gij mwpNtd;. 
 
gq;Nfw;gthpd; ifnahg;gk;____________ 
,lk;_________________         Njjp__________________  
 
gq;Nfw;gtupd; ngaH kw;Wk; tpyhrk;  
rhl;rpahshpd; ifnahg;gk; 
 
,lk;_____________ Njjp___________________  
rhl;rpahshpd; ngaH kw;Wk; tpyhrk; 
  
Ma;thshpd; ifnahg;gk; 
,lk;_____________ Njjp____________________ 
Ma;thshpd; ngaH__________________________   
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